

Greater Manchester Medicines Management Group

Minutes of the meeting held on
Thursday 11th November 2021, 1- 3pm

Virtual meeting

Present:

Name	Title	Organisation	Representing	Oct	Nov 20	May 21	Jun	Aug	Oct	Nov
Dr Helen Burgess (HB)	GP MO Prescribing lead	NHS Manchester CCGs	GPs	✓	✓	✓	✓	✓	A	✓
Petra Brown (PeB)	Chief Pharmacist	Pennine care NHS FT	GM Mental Health Organisations	✓	✓	✓	✓	✓	✓	✓
Kate Rigden (KR)	Chief Finance Officer	NHS Oldham CCG	CCG finance leads	✓	✓	✓	A	AF	✓	✓
Jay Hamilton (TBC)		HiM	Health Innovation Manchester (HiM)							
Dr Ann Harrison (AH)	GP MO Prescribing lead	Trafford CCG	GPs	✓	✓	✓	✓	✓	✓	✓
Robert Hallworth (RH)	Specialist Cancer Pharmacist	NHSE	NHSE Specialised Commissioning	✓	✓	✓	✓	✓	✓	✓
Peter Howarth (PH)	Head of Medicines Management	Tameside & Glossop CCG	CCG MO leads	✓	✓	✓	✓	✓	✓	✓

Aneet Kapoor	Chair of the GM LPN	LPN	Pharmacy profession					✓	✓	✓
Dr Daljit Saroya	Consultant Anaesthetist and Chair of MO committee at Stockport FT	Stockport FT	GM Secondary Care Clinicians	✓						
Leigh Lord (LL)	Locality Lead Pharmacist	NHS Trafford CCG	CCG MO leads	✓	✓	✓	CH	✓	✓	✓
Peter Marks (PM)	LPC Board Member	GM LPC	Community Pharmacy	✓	✓	A	✓	✓	✓	✓
Luvjit Kandula (LK)	Chair – Community Pharmacy Provider Board (CPPB)	GM LPC	Community Pharmacy			✓		✓		A
Fiona Meadowcroft (FC)	Interim Deputy Director Strategy – Integrated Care	MHCC	CCG Commissioning lead	✓	✓	✓	✓	✓	✓	✓
Karen O'Brien (KO'B)	Regional Pharmacist	NHSEI	NHSEI	✓	✓	✓	✓	✓	✓	✓
Rob Bellingham	Managing Director Greater Manchester Joint Commissioning Team	The GM Joint Commissioning Board (MO)	Joint Commissioning Board						✓	✓
Paul Buckley (PaB)	Chief Pharmacist	Stockport FT	GM Chief pharmacists			✓	✓	✓	A	✓
Steve Simpson (SS)	Chief Pharmacist	Bolton FT	GM Chief pharmacists	✓	✓	✓	✓	A	✓	✓
Charlotte Skitterall (CS)	Chief Pharmacist	Manchester FT	Chair	✓	✓	✓	✓	✓	✓	✓
Claire Vaughan (CV)	Head of MO	Salford CCG	Vice Chair	✓	✓	✓	✓	A	✓	✓
Dr Sanjay Wahie	Clinical Director	NHS Wigan CCG	GPs	✓	A	✓	✓	A	✓	✓

(SW)										
Dr Peter Elton	SCN representatives	Strategic Clinical Network	Strateic Clinical Network	✓	✓	✓	✓	✓	A	✓
Vacant seat			Provider Board representative							
Vacant seat			Council representative for GM Social Services							
Vacant seat			GM Medical Directors							
Vacant seat			Lay representative							
Vacant seat			GM Public Health							
Sue Dickinson (SD)	Director of Pharmacy	RDTC	SPS	✓	✓	✓	✓	A	✓	A
Monica Mason (MM)	Head of Prescribing Support	RDTC	Professional secretary	✓	✓	✓	✓	✓	✓	✓
Andrew Martin (AM)	MO Pharmacist	GM Joint Commissioning team	GMMMGM support	✓	✓	✓	✓	✓	✓	✓
Andrew White (AW)	Head of MO	GM Joint Commissioning team	GMMMGM support	✓	✓	✓	✓	✓	✓	✓
Dan Newsome (DN)	Principal pharmacist	RDTC	GMMMGM support	✓	✓				✓	✓

1. General Business

1.1 Apologies

As above. It was noted that the HiM seat is now vacant, but Tracey Vell attended from HiM to support the discussions on inclisiran

1.2 Declarations of Interest

Nil declared

2.0 Minutes and actions from the last meeting

The minutes of the October meeting were approved for publication; the group were updated on the progress of outstanding actions as recorded in the action log notably:

Pharmacy (IPMO) leadership group – will be considering first draft transformation plan at their meeting tomorrow.

Rebate Framework – changes to the framework going out for GM consultation, approval of rebate schemes will continue to operate under the current working until new framework is approved by GMMMG.

nMABs working group – a paper went to GOLD asking for oversight and project management support and is expected back next week, although there will now be a focus on antivirals.

3.0 Subgroup decisions for ratification

GMMMG approved the recommendations made by CRG and MGSG. Barriers to estimating the accurate cost impact of NICE TA715 (moderate RA) were discussed. It was agreed that a provider finance representative should join the primary care finance representation on GMMMG. This will be actioned in the membership review.

Action: MM to include Trust finance representation in the revisions to the GMMMG membership.

4.0 Implementation of national direction on inclisiran across GM

Dr Tracey Vell representing Health Innovation Manchester attended GMMMG to answer questions on the programme of work being led by HiM around inclisiran.

GMMMG approved inclisiran for addition to the formulary with a green status, and noted the financial impact but recognised that this was part of a nationally directed programme.

There was recognition that primary care prescribers would need to be supported pending the arrival of implementation advice nationally by the AHSN, and PH and CV agreed to share their local implementation summaries with MGSG for GM wide sharing.

Action: MGSG to look to develop GM wide implementation guidance pending AHSN implementation materials being published.

HiM (TV) to share slide set with GMMMG

5.0 GM Community Pharmacy Update

Deferred to future meeting

6.0 GM Primary Care Network Update

Juliet Bell presented an update on the PCN work streams to GMMMG, it was agreed that these work streams should be optimised via inclusion within the GM Medicines Strategy (GMMMG + IPMO work streams).

Action: Pharmacy leaders group to discuss incorporation into the GM medicines plan

7.0 GM Value Proposal

GMMMG were updated on the progress of the GM medicines value proposal, and highlighted the next steps being undertaken by GM CCGs and JCT.

GMMMG noted the content of this paper and supported the proposed next steps.

Action: No action for GMMMG at this stage

8.0 Commissioning of Shared Care across GM – progress report

GMMMG considered a paper discussing the current shared care commissioning arrangements across GM, and areas which may require improvement. GMMMG were asked to approve the paper for submission to the GM Primary care cell and GM Medical Executive. GMMMG asked that further discussions be undertaken system wide to better understand and clarify some of the points raised , and that a proposal paper be returned to GMMMG.

Action: AW to redraft as a proposal paper to be approved by GMMMG prior to submission to the primary care cell

9.0 GMEUR service review – implications for the management of high cost drugs outside routine commissioning

GMMMG considered the consequences of changes to the GM EUR service due in April 2022, further comments on these changes were requested from GMMMG members.

Action: GMMMG members to submit comments on this review to Lynne Duxbury and Sarah Maynard of the EUR team, or AW

10.0 High Cost Drug Assurance Monitor

This item was deferred to a future meeting, it was noted that GMMMG Chairs had met with JCT to discuss the content of this paper and that submission to Dec GMMMG is expected

11.0 GMMMG work plan assurance monitor

GMMMG considered the workplan monitor, it was agreed that this information should be communicated to the relevant subgroups, to consider those areas requiring improvement, and revised targets and outcome measures before being returned to GMMMG as part of the Medicines Plan for the Medicines Board.

12.0 Communication from Subgroups and Associated Committees

Due to insufficient time members were asked to share anything significant with the group by email.

Date of next virtual meeting: Thursday 9th December 2021, 1 – 3pm (*this meeting was stood down*)